Patent wars: what’s behind Amgen’s possible win over Sanofi at the US Supreme Court
Pharmaceutical Technology
FEBRUARY 22, 2023
Both drugs come with a high price tag. On the other side, Sanofi argues that Amgen’s patent claim is not enabled because it covers thousands of possible antibodies, but the patent application only highlights a few examples, he adds. Both drugs are monoclonal antibodies that inhibit the protein PCSK9.
Let's personalize your content